reference_id,authors,title,journal,year,volume,citation_footer,citation_type,citation,urls,pubmed_id,doi,header,reference_type,study_id,exclusion_reason,PUBMED_ID_TITLE_AUTHORS,PUBMED_ID_TITLE,PUBMED_ID_S2,N_CITATIONS,S2_PDF_LINK,CORE_PDF_LINK,PUBMED_ID
CD015395-bib-0001,"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al, EPIC-HR Investigators. ","Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19", New England Journal of Medicine ,2022,386,    ,['citation-journal']," Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19.  New England Journal of Medicine 2022;386:1397-408. CENTRAL [DOI: 10.1056/NEJMoa2118542]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1056/NEJMoa2118542', 'https://www.ncbi.nlm.nih.gov/pubmed/35172054', 'https://scholar.google.com/scholar_lookup?title=Oral+nirmatrelvir+for+high-risk,+nonhospitalized+adults+with+COVID-19&author=J+Hammond&author=H+Leister-Tebbe&author=A+Gardner&author=P+Abreu&author=W+Bao&author=W+Wisemandle&publication_year=2022&hl=en']",35172054,https://doi.org/10.1056/NEJMoa2118542, EPIC‐HR 2021 {published data only}  ,included,CD015395-bbs2-0001,,,,,,,,35172054
CD015395-bib-0002,Norisuke K. ,jRCT2031210267: A study of PF-07321332/ritonavir in nonhospitalized high risk adult participants with COVID-19,,,,   ,['citation-other'], Norisuke K. jRCT2031210267: A study of PF-07321332/ritonavir in nonhospitalized high risk adult participants with COVID-19. jrct.niph.go.jp/en-latest-detail/jRCT2031210267 2021 (first received April 11 2022). CENTRAL    ,[''],,, EPIC‐HR 2021 {published data only}  ,included,CD015395-bbs2-0001,,,,,,,,
CD015395-bib-0003,Pfizer. ,2021-002895-38: A phase 2/3 efficacy and safety study of PF-07321332 /ritonavir in nonhospitalized high risk adult participants with COVID 19,,,,   ,['citation-other'], Pfizer. 2021-002895-38: A phase 2/3 efficacy and safety study of PF-07321332 /ritonavir in nonhospitalized high risk adult participants with COVID 19. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38 2021 (first received April 11 2022). CENTRAL    ,[''],,, EPIC‐HR 2021 {published data only}  ,included,CD015395-bbs2-0001,,,,,,,,
CD015395-bib-0004,Pfizer. ,NCT04960202: EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19,,,,   ,['citation-other'], Pfizer. NCT04960202: EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04960202 2021 (first received April 11 2022). CENTRAL    ,[''],,, EPIC‐HR 2021 {published data only}  ,included,CD015395-bbs2-0001,,,,,,,,
CD015395-bib-0005,"Caceres J, Maki DG, Hennekens CH. ",Cautious optimism and considerations for health providers and patients: oral antiviral for early treatment of high-risk patients and vaccines for prevention of COVID-19, American Journal of Medicine ,2022,135,    ,['citation-journal']," Caceres J, Maki DG, Hennekens CH. Cautious optimism and considerations for health providers and patients: oral antiviral for early treatment of high-risk patients and vaccines for prevention of COVID-19.  American Journal of Medicine 2022;135(7):808-9. CENTRAL [DOI: 10.1016/j.amjmed.2022.02.041]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjmed.2022.02.041', 'https://www.ncbi.nlm.nih.gov/pubmed/35307362', 'https://scholar.google.com/scholar_lookup?title=Cautious+optimism+and+considerations+for+health+providers+and+patients:+oral+antiviral+for+early+treatment+of+high-risk+patients+and+vaccines+for+prevention+of+COVID-19+&author=J+Caceres&author=DG+Maki&author=CH+Hennekens&publication_year=2022&hl=en']",35307362,https://doi.org/10.1016/j.amjmed.2022.02.041, Caceres 2022 {published data only}  ,excluded,CD015395-bbs2-0002," Editorial, commentary, letter etc. ",35307362,35307362,,,,,35307362
CD015395-bib-0006,"Elliott W, Chan J. ",Nirmatrelvir and ritonavir tablets (Paxlovid), Internal Medicine Alert ,2022,44,    ,['citation-journal']," Elliott W, Chan J. Nirmatrelvir and ritonavir tablets (Paxlovid).  Internal Medicine Alert 2022;44(1):Issue date: January 15, 2022. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Nirmatrelvir+and+ritonavir+tablets+(Paxlovid)&author=W+Elliott&author=J+Chan&publication_year=2022&hl=en']",,, Elliott 2022 {published data only}  ,excluded,CD015395-bbs2-0003," Editorial, commentary, letter etc. ",,,,,,,
CD015395-bib-0007,Pfizer Inc. ,"A phase 2/3 safety, pharmacokinetics, and efficacy study of nirmatrelvir/ritonavir in pediatric, nonhospitalized symptomatic participantswWith COVID-19 who are at risk of progression to severe disease",,,,   ,['citation-other']," Pfizer Inc. A phase 2/3 safety, pharmacokinetics, and efficacy study of nirmatrelvir/ritonavir in pediatric, nonhospitalized symptomatic participantswWith COVID-19 who are at risk of progression to severe disease. clinicaltrials.gov/ct2/show/NCT05261139 2022 (accessed May 15 2022). CENTRAL    ",[''],,, EPIC‐PEDS 2022 {published data only}  ,excluded,CD015395-bbs2-0004, Ineligible study design ,,,,,,,
CD015395-bib-0008,Shionogi Clinical Trials Administrator. ,NCT05305547. A study to compare S-217622 with placebo in non-hospitalized high-risk participants with COVID-19,,,,   ,['citation-other'], Shionogi Clinical Trials Administrator. NCT05305547. A study to compare S-217622 with placebo in non-hospitalized high-risk participants with COVID-19. clinicaltrials.gov/ct2/show/NCT05305547 2022 (accessed April 11 2022). CENTRAL    ,[''],,, NCT05305547 {published data only}  ,excluded,CD015395-bbs2-0005, Ineligible intervention: study drug S‐217622 ,,,,,,,
CD015395-bib-0009,"Singh RS, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, et al. ",Innovative randomized phase 1 study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir [online ahead of print],,2022,,    ,['citation-other']," Singh RS, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, et al. Innovative randomized phase 1 study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir [online ahead of print]. Clinical Pharmacology & Therapeutics2022. CENTRAL [DOI: 10.1002/cpt.2603]    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Innovative+randomized+phase+1+study+and+dosing+regimen+selection+to+accelerate+and+inform+pivotal+COVID-19+trial+of+nirmatrelvir+[online+ahead+of+print]+&author=RS+Singh&author=SS+Toussi&author=F+Hackman&author=PL+Chan&author=R+Rao&author=R+Allen&publication_year=2022&hl=en']",,, Singh 2022 {published data only}  ,excluded,CD015395-bbs2-0006, Ineligible patient population: healthy adults ,,,,,,,
CD015395-bib-0010,"Singh Rsp, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, et al. ",Innovative randomized phase 1 study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir, medRxiv ,2022,2022.02.08,    ,['citation-journal']," Singh Rsp, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, et al. Innovative randomized phase 1 study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir.  medRxiv 2022;2022.02.08:22270649. CENTRAL [DOI: 10.1101/2022.02.08.22270649]    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Innovative+randomized+phase+1+study+and+dosing+regimen+selection+to+accelerate+and+inform+pivotal+COVID-19+trial+of+nirmatrelvir+&author=SS+Toussi&author=F+Hackman&author=PL+Chan&author=R+Rao&author=R+Allen&publication_year=2022&hl=en']",,, Singh 2022 {published data only}  ,excluded,CD015395-bbs2-0006, Ineligible patient population: healthy adults ,,,,,,,
CD015395-bib-0011,"Wang Z, Yang L. ",In the age of omicron variant: Paxlovid raises new hopes of COVID-19 recovery, Journal of Medical Virology ,2022,94,    ,['citation-journal']," Wang Z, Yang L. In the age of omicron variant: Paxlovid raises new hopes of COVID-19 recovery.  Journal of Medical Virology 2022;94(5):1766-7. CENTRAL [DOI: 10.1002/jmv.27540]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1002/jmv.27540', 'https://www.ncbi.nlm.nih.gov/pubmed/34936106', 'https://scholar.google.com/scholar_lookup?title=In+the+age+of+omicron+variant:+Paxlovid+raises+new+hopes+of+COVID-19+recovery&author=Z+Wang&author=L+Yang&publication_year=2022&hl=en']",34936106,https://doi.org/10.1002/jmv.27540, Wang 2022 {published data only}  ,excluded,CD015395-bbs2-0007," Editorial, commentary, letter etc. ",,34936106,,,,,34936106
CD015395-bib-0024,"Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. ",A living WHO guideline on drugs for covid-19, BMJ ,,370,    ,['citation-journal']," Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. A living WHO guideline on drugs for covid-19.  BMJ  2020/09/04;370:m3379. [DOI: 10.1136/bmj.m3379]    Link to article     PubMed     ","['https://doi.org/10.1136/bmj.m3379', 'https://www.ncbi.nlm.nih.gov/pubmed/32887691']",32887691,https://doi.org/10.1136/bmj.m3379, Agarwal 2020 ,additional,CD015395-bbs2-0016,,,,,,,,32887691
CD015395-bib-0025,"Altulahi N, AlNujaim S, Alabdulqader A, Alkharashi A, AlMalki A, AlSiari F, et al. ","Willingness, beliefs, and barriers regarding the COVID-19 vaccine in Saudi Arabia: a multiregional cross-sectional study", BMC Family Practice ,2021,22,    ,['citation-journal']," Altulahi N, AlNujaim S, Alabdulqader A, Alkharashi A, AlMalki A, AlSiari F, et al. Willingness, beliefs, and barriers regarding the COVID-19 vaccine in Saudi Arabia: a multiregional cross-sectional study.  BMC Family Practice 2021;22(1):247. [DOI: 10.1186/s12875-021-01606-6]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/s12875-021-01606-6', 'https://www.ncbi.nlm.nih.gov/pubmed/34911441', 'https://scholar.google.com/scholar_lookup?title=Willingness,+beliefs,+and+barriers+regarding+the+COVID-19+vaccine+in+Saudi+Arabia:+a+multiregional+cross-sectional+study+&author=N+Altulahi&author=S+AlNujaim&author=A+Alabdulqader&author=A+Alkharashi&author=A+AlMalki&author=F+AlSiari&publication_year=2021&hl=en']",34911441,https://doi.org/10.1186/s12875-021-01606-6, Altulahi 2021 ,additional,CD015395-bbs2-0017,,,34911441,,,,,34911441
CD015395-bib-0026,"Amin SA, Banerjee S, Ghosh K, Gayen S, Jha T. ",Protease targeted COVID-19 drug discovery and its challenges: insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors, Bioorganic & Medicinal Chemistry ,2021,29,    ,['citation-journal']," Amin SA, Banerjee S, Ghosh K, Gayen S, Jha T. Protease targeted COVID-19 drug discovery and its challenges: insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.  Bioorganic & Medicinal Chemistry 2021;29:115860. [PMID: 33191083]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.bmc.2020.115860', 'https://www.ncbi.nlm.nih.gov/pubmed/33191083', 'https://scholar.google.com/scholar_lookup?title=Protease+targeted+COVID-19+drug+discovery+and+its+challenges:+insight+into+viral+main+protease+(Mpro)+and+papain-like+protease+(PLpro)+inhibitors+&author=SA+Amin&author=S+Banerjee&author=K+Ghosh&author=S+Gayen&author=T+Jha&publication_year=2021&hl=en']",33191083,https://doi.org/10.1016/j.bmc.2020.115860, Amin 2021 ,additional,CD015395-bbs2-0018,,33191083,33191083,,,,,33191083
CD015395-bib-0027,"Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. ",Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs, Science ,2003,300,    ,['citation-journal']," Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.  Science 2003;300(5626):1763-7. [PMID: 12746549]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1126/science.1085658', 'https://www.ncbi.nlm.nih.gov/pubmed/12746549', 'https://scholar.google.com/scholar_lookup?title=Coronavirus+main+proteinase+(3CLpro)+structure:+basis+for+design+of+anti-SARS+drugs&author=K+Anand&author=J+Ziebuhr&author=P+Wadhwani&author=JR+Mesters&author=R+Hilgenfeld&publication_year=2003&hl=en']",12746549,https://doi.org/10.1126/science.1085658, Anand 2003 ,additional,CD015395-bbs2-0019,,12746549,12746549,,,,,12746549
CD015395-bib-0028,"Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. ",GRADE guidelines – 3: rating the quality of evidence, Journal of Clinical Epidemiology ,2011,64,    ,['citation-journal']," Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines – 3: rating the quality of evidence.  Journal of Clinical Epidemiology 2011;64(4):401-6. [PMID: 21208779]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.jclinepi.2010.07.015', 'https://www.ncbi.nlm.nih.gov/pubmed/21208779', 'https://scholar.google.com/scholar_lookup?title=GRADE+guidelines+–+3:+rating+the+quality+of+evidence&author=H+Balshem&author=M+Helfand&author=HJ+Schünemann&author=AD+Oxman&author=R+Kunz&author=J+Brozek&publication_year=2011&hl=en']",21208779,https://doi.org/10.1016/j.jclinepi.2010.07.015, Balshem 2011 ,additional,CD015395-bbs2-0020,,,,,,,,21208779
CD015395-bib-0029,"Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. ",Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis, PLOS One ,2021,16,    ,['citation-journal']," Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis.  PLOS One 2021;16(3):e0247461. [PMID: 33661992]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1371/journal.pone.0247461', 'https://www.ncbi.nlm.nih.gov/pubmed/33661992', 'https://scholar.google.com/scholar_lookup?title=Population+risk+factors+for+severe+disease+and+mortality+in+COVID-19:+a+global+systematic+review+and+meta-analysis+&author=A+Booth&author=AB+Reed&author=S+Ponzo&author=A+Yassaee&author=M+Aral&author=D+Plans&publication_year=2021&hl=en']",33661992,https://doi.org/10.1371/journal.pone.0247461, Booth 2021 ,additional,CD015395-bbs2-0021,,,,,,,,33661992
CD015395-bib-0030,Bramstedt KA. ,The carnage of substandard research during the COVID-19 pandemic: a call for quality, Journal of Medical Ethics ,2020,46,    ,['citation-journal'], Bramstedt KA. The carnage of substandard research during the COVID-19 pandemic: a call for quality.  Journal of Medical Ethics 2020;46:803-7. [PMID: 33004545]    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1136/medethics-2020-106494', 'https://www.ncbi.nlm.nih.gov/pubmed/33004545', 'https://scholar.google.com/scholar_lookup?title=The+carnage+of+substandard+research+during+the+COVID-19+pandemic:+a+call+for+quality&author=KA+Bramstedt&publication_year=2020&hl=en']",33004545,https://doi.org/10.1136/medethics-2020-106494, Bramstedt 2020 ,additional,CD015395-bbs2-0022,,,,,,,,33004545
CD015395-bib-0031,Centers for Disease Control and Prevention (CDC). ,Benefits of getting a COVID-19 vaccine,,,,. cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html (accessed 14 December 2021).   ,['citation-other'], Centers for Disease Control and Prevention (CDC). Benefits of getting a COVID-19 vaccine. cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html (accessed 14 December 2021).    ,[],,, CDC 2021 ,additional,CD015395-bbs2-0023,,37602945,,,,,,37602945
CD015395-bib-0032,"Chen S, Jonas F, Shen C, Hilgenfeld R. ",Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode, Protein Cell ,2010,1,    ,['citation-journal']," Chen S, Jonas F, Shen C, Hilgenfeld R. Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode.  Protein Cell 2010;1(1):59-74. [PMID: 21203998]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1007/s13238-010-0011-4', 'https://www.ncbi.nlm.nih.gov/pubmed/21203998', 'https://scholar.google.com/scholar_lookup?title=Liberation+of+SARS-CoV+main+protease+from+the+viral+polyprotein:+N-terminal+autocleavage+does+not+depend+on+the+mature+dimerization+mode+&author=S+Chen&author=F+Jonas&author=C+Shen&author=R+Hilgenfeld&publication_year=2010&hl=en']",21203998,https://doi.org/10.1007/s13238-010-0011-4, Chen 2010 ,additional,CD015395-bbs2-0024,,,,,,,,21203998
CD015395-bib-0033,,Cochrane Database of Systematic Reviews: editorial policies. Cochrane policy on managing potentially problematic studies,,,,. cochranelibrary.com/cdsr/editorial-policies#problematic-studies (assessed 04 April 2022).   ,['citation-other'], Cochrane Database of Systematic Reviews: editorial policies. Cochrane policy on managing potentially problematic studies. cochranelibrary.com/cdsr/editorial-policies#problematic-studies (assessed 04 April 2022).    ,[],,, Cochrane policy ‐ managing problematic studies ,additional,CD015395-bbs2-0025,,26006174,,,,,,26006174
CD015395-bib-0034,Core Outcome Measures in Effectiveness Trials (COMET) Initiative. ,Core outcome set developers’ response to COVID-19,,,,. comet-initiative.org/Studies/Details/1538 (accessed 13 June 2021).   ,['citation-other'], Core Outcome Measures in Effectiveness Trials (COMET) Initiative. Core outcome set developers’ response to COVID-19. comet-initiative.org/Studies/Details/1538 (accessed 13 June 2021).    ,[],,, COMET 2020 ,additional,CD015395-bbs2-0026,,38359962,,,,,,38359962
CD015395-bib-0035,"Dai W, Zhang B, Jiang X-M, Su H, Li J, Zhao Y, et al. ",Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease, Science ,2020,368,    ,['citation-journal']," Dai W, Zhang B, Jiang X-M, Su H, Li J, Zhao Y, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.  Science 2020;368(6497):1331-5. [PMID: 32321856]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1126/science.abb4489', 'https://www.ncbi.nlm.nih.gov/pubmed/32321856', 'https://scholar.google.com/scholar_lookup?title=Structure-based+design+of+antiviral+drug+candidates+targeting+the+SARS-CoV-2+main+protease+&author=W+Dai&author=B+Zhang&author=H+Su&author=J+Li&author=Y+Zhao&publication_year=2020&hl=en']",32321856,https://doi.org/10.1126/science.abb4489, Dai 2020 ,additional,CD015395-bbs2-0027,,,,,,,,32321856
CD015395-bib-0036,Cochrane Pregnancy and Childbirth Group. ,pcg_data_extraction_form_v_2.2_-_13_july_2021_1.docx,,,,. pregnancy.cochrane.org/author-resources-new-reviews (accessed 9 December 2021).   ,['citation-other'], Cochrane Pregnancy and Childbirth Group. pcg_data_extraction_form_v_2.2_-_13_july_2021_1.docx. pregnancy.cochrane.org/author-resources-new-reviews (accessed 9 December 2021).    ,[],,, Data extraction template 2021 ,additional,CD015395-bbs2-0028,,,,,,,,
CD015395-bib-0037,"Deeks JJ, Higgins JP, Altman DG. ","Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022",,,,. Available from training.cochrane.org/handbook.   ,['citation-other']," Deeks JJ, Higgins JP, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.    ",[],,, Deeks 2022 ,additional,CD015395-bbs2-0029,,,,,,,,
CD015395-bib-0038,"Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. ",Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study, Journal of Infection ,2020,81,    ,['citation-journal']," Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study.  Journal of Infection 2020;81(1):e1-5. [PMID: 32171872]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.jinf.2020.03.002', 'https://www.ncbi.nlm.nih.gov/pubmed/32171872', 'https://scholar.google.com/scholar_lookup?title=Arbidol+combined+with+LPV/r+versus+LPV/r+alone+against+corona+virus+disease+2019:+a+retrospective+cohort+study+&author=L+Deng&author=C+Li&author=Q+Zeng&author=X+Liu&author=X+Li&author=H+Zhang&publication_year=2020&hl=en']",32171872,https://doi.org/10.1016/j.jinf.2020.03.002, Deng 2020 ,additional,CD015395-bbs2-0030,,,32171872,,,,,32171872
CD015395-bib-0039,"de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O’Connor R, et al. ",Comparative study of a 3CL pro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models, bioRxiv ,2020 ,95,    ,['citation-journal']," de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O’Connor R, et al. Comparative study of a 3CL pro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models.  bioRxiv 2020 ;95(10):1819-20. [DOI: 10.1101/2020.08.28.272880]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Comparative+study+of+a+3CL+pro+inhibitor+and+remdesivir+against+both+major+SARS-CoV-2+clades+in+human+airway+models+&author=M+Vries&author=AS+Mohamed&author=RA+Prescott&author=AM+Valero-Jimenez&author=L+Desvignes&author=R+O’Connor&publication_year=2020\xa0&hl=en'],,, de Vries 2020 ,additional,CD015395-bbs2-0031,,,,,,,,
CD015395-bib-0040,"Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al . ","Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection", Cochrane Database of Systematic Reviews ,2021,,    ,['citation-journal']," Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al . Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.  Cochrane Database of Systematic Reviews 2021, Issue 3. Art. No: CD013705. [DOI: 10.1002/14651858.CD013705]    Google Scholar     ","['https://scholar.google.com/scholar_lookup?title=Rapid,+point-of-care+antigen+and+molecular-based+tests+for+diagnosis+of+SARS-CoV-2+infection+&author=J+Dinnes&author=JJ+Deeks&author=S+Berhane&author=M+Taylor&author=A+Adriano&author=C+Davenport&publication_year=2021&hl=en']",,, Dinnes 2021 ,additional,CD015395-bbs2-0032,,,,,,,,
CD015395-bib-0041,"Eloy P, Le Grand R, Malvy D, Guedj J. ",Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?, eBioMedicine ,2021,74,    ,['citation-journal']," Eloy P, Le Grand R, Malvy D, Guedj J. Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two? eBioMedicine 2021;74:103663. [DOI: 10.1016/j.ebiom.2021.103663]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.ebiom.2021.103663', 'https://www.ncbi.nlm.nih.gov/pubmed/34768087', 'https://scholar.google.com/scholar_lookup?title=Combined+treatment+of+molnupiravir+and+favipiravir+against+SARS-CoV-2+infection:+One+++zero+equals+two?+&author=P+Eloy&author=R+LeGrand&author=D+Malvy&author=J+Guedj&publication_year=2021&hl=en']",34768087,https://doi.org/10.1016/j.ebiom.2021.103663, Eloy 2021 ,additional,CD015395-bbs2-0033,,34768087,34768087,,,,,34768087
CD015395-bib-0042,,EndNote,,2013,,.   ,['citation-other']," EndNote. Version EndNote 20. Philadelphia, PA: Clarivate, 2013.    ",[],,, EndNote 2013 [Computer program] ,additional,CD015395-bbs2-0034,,41692600,,,,,,41692600
CD015395-bib-0043,US Food and Drug Administration (FDA). ,Fact sheet for healthcare providers: Emergency Use Authorization for Paxlovid,,,,. www.fda.gov/media/155050/download (accessed 14 February 2022).   ,['citation-other'], US Food and Drug Administration (FDA). Fact sheet for healthcare providers: Emergency Use Authorization for Paxlovid. www.fda.gov/media/155050/download (accessed 14 February 2022).    ,[],,, EUA for Paxlovid ,additional,CD015395-bbs2-0035,,,,,,,,
CD015395-bib-0044,"Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. ",SARS-CoV-2 viral load is associated with increased disease severity and mortality, Nature Communications ,2020,11,    ,['citation-journal']," Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality.  Nature Communications 2020;11(1):5493. [PMID: 33127906]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1038/s41467-020-19057-5', 'https://www.ncbi.nlm.nih.gov/pubmed/33127906', 'https://scholar.google.com/scholar_lookup?title=SARS-CoV-2+viral+load+is+associated+with+increased+disease+severity+and+mortality&author=J+Fajnzylber&author=J+Regan&author=K+Coxen&author=H+Corry&author=C+Wong&author=A+Rosenthal&publication_year=2020&hl=en']",33127906,https://doi.org/10.1038/s41467-020-19057-5, Fajnzylber 2020 ,additional,CD015395-bbs2-0036,,,,,,,,33127906
CD015395-bib-0045,"Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, et al. ","Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021", Euro Surveillance ,2021,26,    ,['citation-journal']," Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.  Euro Surveillance 2021;26(16):2100348. [PMID: 33890566]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348', 'https://www.ncbi.nlm.nih.gov/pubmed/33890566', 'https://scholar.google.com/scholar_lookup?title=Characteristics+of+SARS-CoV-2+variants+of+concern+B.1.1.7,+B.1.351+or+P.1:+data+from+seven+EU/EEA+countries,+weeks+38/2020+to+10/2021+&author=T+Funk&author=A+Pharris&author=G+Spiteri&author=N+Bundle&author=A+Melidou&author=M+Carr&publication_year=2021&hl=en']",33890566,https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348, Funk 2021 ,additional,CD015395-bbs2-0037,,,,,,,,33890566
CD015395-bib-0046,"Blankenfeld H, Kaduszkiewicz H, Kochen MM, Pömsl J. ",[SARS-CoV-2/Covid-19 Informationen und Praxishilfen für niedergelassene Hausärztinnen und Hausärzte],,,,. awmf.org/leitlinien/detail/ll/053-054.html (accessed 14 February 2022).   ,['citation-other']," Blankenfeld H, Kaduszkiewicz H, Kochen MM, Pömsl J. [SARS-CoV-2/Covid-19 Informationen und Praxishilfen für niedergelassene Hausärztinnen und Hausärzte]. awmf.org/leitlinien/detail/ll/053-054.html (accessed 14 February 2022).    ",[],,, German AWMF Guideline 2021 ,additional,CD015395-bbs2-0038,,,,,,,,
CD015395-bib-0047,"Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. ",Early remdesivir to prevent progression to severe Covid-19 in outpatients, New England Journal of Medicine ,2022,386,    ,['citation-journal']," Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients.  New England Journal of Medicine 2022;386(4):305-15. [PMID: 34937145]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1056/NEJMoa2116846', 'https://www.ncbi.nlm.nih.gov/pubmed/34937145', 'https://scholar.google.com/scholar_lookup?title=Early+remdesivir+to+prevent+progression+to+severe+Covid-19+in+outpatients&author=RL+Gottlieb&author=CE+Vaca&author=R+Paredes&author=J+Mera&author=BJ+Webb&author=G+Perez&publication_year=2022&hl=en']",34937145,https://doi.org/10.1056/NEJMoa2116846, Gottlieb 2022 ,additional,CD015395-bbs2-0039,,,,,,,,34937145
CD015395-bib-0048,"Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. ","The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries", PLOS One ,2020,15,    ,['citation-journal']," Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries.  PLOS One 2020;15(6):e0234765. [PMID: 32574165]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1371/journal.pone.0234765', 'https://www.ncbi.nlm.nih.gov/pubmed/32574165', 'https://scholar.google.com/scholar_lookup?title=The+prevalence+of+symptoms+in+24,410+adults+infected+by+the+novel+coronavirus+(SARS-CoV-2;+COVID-19):+a+systematic+review+and+meta-analysis+of+148+studies+from+9+countries+&author=MC+Grant&author=L+Geoghegan&author=M+Arbyn&author=Z+Mohammed&author=L+McGuinness&author=EL+Clarke&publication_year=2020&hl=en']",32574165,https://doi.org/10.1371/journal.pone.0234765, Grant 2020 ,additional,CD015395-bbs2-0040,,,,,,,,32574165
CD015395-bib-0049,"Grey A, Bolland MJ, Avenell A, Klein AA, Gunsalus CK. ",Check for publication integrity before misconduct, Nature ,2020,577,    ,['citation-journal']," Grey A, Bolland MJ, Avenell A, Klein AA, Gunsalus CK. Check for publication integrity before misconduct.  Nature 2020;577(7789):167-9. [PMID: 31911697]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1038/d41586-019-03959-6', 'https://www.ncbi.nlm.nih.gov/pubmed/31911697', 'https://scholar.google.com/scholar_lookup?title=Check+for+publication+integrity+before+misconduct&author=A+Grey&author=MJ+Bolland&author=A+Avenell&author=AA+Klein&author=CK+Gunsalus&publication_year=2020&hl=en']",31911697,https://doi.org/10.1038/d41586-019-03959-6, Grey 2020 ,additional,CD015395-bbs2-0041,,31911697,,,,,,31911697
CD015395-bib-0050,"Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. ","SARS-CoV-2 variants, spike mutations and immune escape", Nature Reviews Microbiology ,2021,19,    ,['citation-journal']," Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape.  Nature Reviews Microbiology 2021;19(7):409-24. [PMID: 34075212]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1038/s41579-021-00573-0', 'https://www.ncbi.nlm.nih.gov/pubmed/34075212', 'https://scholar.google.com/scholar_lookup?title=SARS-CoV-2+variants,+spike+mutations+and+immune+escape&author=WT+Harvey&author=AM+Carabelli&author=B+Jackson&author=RK+Gupta&author=EC+Thomson&author=EM+Harrison&publication_year=2021&hl=en']",34075212,https://doi.org/10.1038/s41579-021-00573-0, Harvey 2021 ,additional,CD015395-bbs2-0042,,,,,,,,34075212
CD015395-bib-0051,"Higgins JP, Lasserson T, Chandler J, Tovey D, Thomas J, Flemyng E, et al. ",Methodological Expectations of Cochrane Intervention Reviews (MECIR),,,,. community.cochrane.org/mecir-manual/ (accessed 12 December 2021).   ,['citation-other']," Higgins JP, Lasserson T, Chandler J, Tovey D, Thomas J, Flemyng E, et al. Methodological Expectations of Cochrane Intervention Reviews (MECIR). community.cochrane.org/mecir-manual/ (accessed 12 December 2021).    ",[],,, Higgins 2021 ,additional,CD015395-bbs2-0043,,,,,,,,
CD015395-bib-0052,"Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. ","Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022",,,,. Available from training.cochrane.org/handbook.   ,['citation-other']," Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.    ",[],,, Higgins 2022a ,additional,CD015395-bbs2-0044,,,,,,,,
CD015395-bib-0053,"Higgins JP, Li T, Deeks JJ, editor(s). ","Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022",,,,. Available from training.cochrane.org/handbook.   ,['citation-other']," Higgins JP, Li T, Deeks JJ, editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.    ",[],,, Higgins 2022b ,additional,CD015395-bbs2-0045,,,,,,,,
CD015395-bib-0054,"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. ","Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet ,2020,395,    ,['citation-journal']," Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.  Lancet 2020;395(10223):497-506. [PMID: 31986264]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(20)30183-5', 'https://www.ncbi.nlm.nih.gov/pubmed/31986264', 'https://scholar.google.com/scholar_lookup?title=Clinical+features+of+patients+infected+with+2019+novel+coronavirus+in+Wuhan,+China&author=C+Huang&author=Y+Wang&author=X+Li&author=L+Ren&author=J+Zhao&author=Y+Hu&publication_year=2020&hl=en']",31986264,https://doi.org/10.1016/S0140-6736(20)30183-5, Huang 2020 ,additional,CD015395-bbs2-0046,,,,,,,,31986264
CD015395-bib-0055,"Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. ",6-month consequences of COVID-19 in patients discharged from hospital: a cohort study, Lancet ,2021,397,    ,['citation-journal']," Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.  Lancet 2021;397(10270):220-32. [PMID: 33428867]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(20)32656-8', 'https://www.ncbi.nlm.nih.gov/pubmed/33428867', 'https://scholar.google.com/scholar_lookup?title=6-month+consequences+of+COVID-19+in+patients+discharged+from+hospital:+a+cohort+study&author=C+Huang&author=L+Huang&author=Y+Wang&author=X+Li&author=L+Ren&author=X+Gu&publication_year=2021&hl=en']",33428867,https://doi.org/10.1016/S0140-6736(20)32656-8, Huang 2021 ,additional,CD015395-bbs2-0047,,,,,,,,33428867
CD015395-bib-0056,"IntHout J, Ioannidis JP, Rovers MM, Goeman JJ. ",Plea for routinely presenting prediction intervals in meta-analysis, BMJ Open ,2016,12,    ,['citation-journal']," IntHout J, Ioannidis JP, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis.  BMJ Open 2016;12(6):e010247. [DOI: 10.1136/bmjopen-2015-010247] [PMID: 27406637]    Link to article     Google Scholar     ","['https://doi.org/10.1136/bmjopen-2015-010247', 'https://scholar.google.com/scholar_lookup?title=Plea+for+routinely+presenting+prediction+intervals+in+meta-analysis&author=J+IntHout&author=JP+Ioannidis&author=MM+Rovers&author=JJ+Goeman&publication_year=2016&hl=en']",,https://doi.org/10.1136/bmjopen-2015-010247, IntHout 2016 ,additional,CD015395-bbs2-0048,,27406637,27406637,,,,,27406637
CD015395-bib-0057,"Juthani PV, Gupta A, Borges KA, Price CC, Lee AI, Won CH, et al. ",Hospitalisation among vaccine breakthrough COVID-19 infections, Lancet Infectious Diseases ,2021,21,    ,['citation-journal']," Juthani PV, Gupta A, Borges KA, Price CC, Lee AI, Won CH, et al. Hospitalisation among vaccine breakthrough COVID-19 infections.  Lancet Infectious Diseases 2021;21(11):1485-6. [DOI: 10.1016/S1473-3099(21)00558-2]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1473-3099(21)00558-2', 'https://www.ncbi.nlm.nih.gov/pubmed/34506735', 'https://scholar.google.com/scholar_lookup?title=Hospitalisation+among+vaccine+breakthrough+COVID-19+infections&author=PV+Juthani&author=A+Gupta&author=KA+Borges&author=CC+Price&author=AI+Lee&author=CH+Won&publication_year=2021&hl=en']",34506735,https://doi.org/10.1016/S1473-3099(21)00558-2, Juthani 2021 ,additional,CD015395-bbs2-0049,,,,,,,,34506735
CD015395-bib-0058,"Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. ","Case characteristics, resource use, and outcomes of 10021 patients with COVID-19 admitted to 920 German hospitals: an observational study", Lancet Respiratory Medicine ,2020,8,    ,['citation-journal']," Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10021 patients with COVID-19 admitted to 920 German hospitals: an observational study.  Lancet Respiratory Medicine 2020;8(9):853-62. [PMID: 32735842]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S2213-2600(20)30316-7', 'https://www.ncbi.nlm.nih.gov/pubmed/32735842', 'https://scholar.google.com/scholar_lookup?title=Case+characteristics,+resource+use,+and+outcomes+of+10021+patients+with+COVID-19+admitted+to+920+German+hospitals:+an+observational+study+&author=C+Karagiannidis&author=C+Mostert&author=C+Hentschker&author=T+Voshaar&author=J+Malzahn&author=G+Schillinger&publication_year=2020&hl=en']",32735842,https://doi.org/10.1016/S2213-2600(20)30316-7, Karagiannidis 2020 ,additional,CD015395-bbs2-0050,,,,,,,,32735842
CD015395-bib-0059,"Kawasuji H, Takegoshi Y, Kaneda M, Ueno A, Miyajima Y, Kawago K, et al. ",Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients, PLOS One ,2020,15,    ,['citation-journal']," Kawasuji H, Takegoshi Y, Kaneda M, Ueno A, Miyajima Y, Kawago K, et al. Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients.  PLOS One 2020;15(12):e0243597. [PMID: 33296437]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1371/journal.pone.0243597', 'https://www.ncbi.nlm.nih.gov/pubmed/33296437', 'https://scholar.google.com/scholar_lookup?title=Transmissibility+of+COVID-19+depends+on+the+viral+load+around+onset+in+adult+and+symptomatic+patients+&author=H+Kawasuji&author=Y+Takegoshi&author=M+Kaneda&author=A+Ueno&author=Y+Miyajima&author=K+Kawago&publication_year=2020&hl=en']",33296437,https://doi.org/10.1371/journal.pone.0243597, Kawasuji 2020 ,additional,CD015395-bbs2-0051,,,33296437,,,,,33296437
CD015395-bib-0060,"Killerby ME, Link-Gelles R, Haight SC, Schrodt CA, England L, Gomes DJ, et al. ","Characteristics associated with hospitalization among patients with COVID-19 - Metropolitan Atlanta, Georgia, March–April 2020", Morbidity and Mortality Weekly Report ,2020,69,    ,['citation-journal']," Killerby ME, Link-Gelles R, Haight SC, Schrodt CA, England L, Gomes DJ, et al. Characteristics associated with hospitalization among patients with COVID-19 - Metropolitan Atlanta, Georgia, March–April 2020.  Morbidity and Mortality Weekly Report 2020;69:790-4. [DOI: 10.15585/mmwr.mm6925e1]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.15585/mmwr.mm6925e1', 'https://www.ncbi.nlm.nih.gov/pubmed/32584797', 'https://scholar.google.com/scholar_lookup?title=Characteristics+associated+with+hospitalization+among+patients+with+COVID-19+-+Metropolitan+Atlanta,+Georgia,+March–April+2020+&author=ME+Killerby&author=R+Link-Gelles&author=SC+Haight&author=CA+Schrodt&author=L+England&author=DJ+Gomes&publication_year=2020&hl=en']",32584797,https://doi.org/10.15585/mmwr.mm6925e1, Killerby 2020 ,additional,CD015395-bbs2-0052,,,32584797,,,,,32584797
CD015395-bib-0061,"Kumar M, Al Khodor S. ",Pathophysiology and treatment strategies for COVID-19, Journal of Translational Medicine ,2020,18,    ,['citation-journal']," Kumar M, Al Khodor S. Pathophysiology and treatment strategies for COVID-19.  Journal of Translational Medicine 2020;18(1):353. [DOI: 10.1186/s12967-020-02520-8]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/s12967-020-02520-8', 'https://www.ncbi.nlm.nih.gov/pubmed/32933536', 'https://scholar.google.com/scholar_lookup?title=Pathophysiology+and+treatment+strategies+for+COVID-19&author=M+Kumar&author=S+AlKhodor&publication_year=2020&hl=en']",32933536,https://doi.org/10.1186/s12967-020-02520-8, Kumar 2020 ,additional,CD015395-bbs2-0053,,32933536,,,,,,32933536
CD015395-bib-0062,"Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Marshall C, et al. ","Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022",,,,. Available from training.cochrane.org/handbook.   ,['citation-other']," Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Marshall C, et al. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.    ",[],,, Lefebvre 2022 ,additional,CD015395-bbs2-0054,,,,,,,,
CD015395-bib-0063,"Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. ",Effectiveness of Covid-19 vaccines over a 9-month period in North Carolina, New England Journal of Medicine ,2022,386,    ,['citation-journal']," Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. Effectiveness of Covid-19 vaccines over a 9-month period in North Carolina.  New England Journal of Medicine 2022;386(10):933-41. [PMID: 35020982]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1056/NEJMoa2117128', 'https://www.ncbi.nlm.nih.gov/pubmed/35020982', 'https://scholar.google.com/scholar_lookup?title=Effectiveness+of+Covid-19+vaccines+over+a+9-month+period+in+North+Carolina&author=DY+Lin&author=Y+Gu&author=B+Wheeler&author=H+Young&author=S+Holloway&author=SK+Sunny&publication_year=2022&hl=en']",35020982,https://doi.org/10.1056/NEJMoa2117128, Lin 2022 ,additional,CD015395-bbs2-0055,,,,,,,,35020982
CD015395-bib-0064,"Liu Y, Yan L, Wan L, Xiang T, Le A, Liu J, et al. ",Viral dynamics in mild and severe cases of COVID-19, Lancet ,2020,20,    ,['citation-journal']," Liu Y, Yan L, Wan L, Xiang T, Le A, Liu J, et al. Viral dynamics in mild and severe cases of COVID-19.  Lancet 2020;20(6):656-7. [PMID: 32199493]    Link to article     Google Scholar     ","['https://doi.org/10.1016/S1473-3099(20)30232-2', 'https://scholar.google.com/scholar_lookup?title=Viral+dynamics+in+mild+and+severe+cases+of+COVID-19&author=Y+Liu&author=L+Yan&author=L+Wan&author=T+Xiang&author=A+Le&author=J+Liu&publication_year=2020&hl=en']",,https://doi.org/10.1016/S1473-3099(20)30232-2, Liu 2020 ,additional,CD015395-bbs2-0056,,,,,,,,
CD015395-bib-0065,"Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, et al. ",A minimal common outcome measure set for COVID-19 clinical research, Lancet Infectious Diseases ,2020,20,    ,['citation-journal']," Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, et al. A minimal common outcome measure set for COVID-19 clinical research.  Lancet Infectious Diseases 2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7] [PMID: 32539990]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1473-3099(20)30483-7', 'https://www.ncbi.nlm.nih.gov/pubmed/32539990', 'https://scholar.google.com/scholar_lookup?title=A+minimal+common+outcome+measure+set+for+COVID-19+clinical+research&author=JC+Marshall&author=S+Murthy&author=J+Diaz&author=NK+Adhikari&author=DC+Angus&author=YM+Arabi&publication_year=2020&hl=en']",32539990,https://doi.org/10.1016/S1473-3099(20)30483-7, Marshall 2020 ,additional,CD015395-bbs2-0057,,,,,,,,32539990
CD015395-bib-0066,Merck. ,Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate Covid-19 in positive interim analysis of phase 3 study,,,,. merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/ (accessed 1 October 2021).   ,['citation-other'], Merck. Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate Covid-19 in positive interim analysis of phase 3 study. merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/ (accessed 1 October 2021).    ,[],,, Merck 2021 ,additional,CD015395-bbs2-0058,,,,,,,,
CD015395-bib-0067,,Meta: General Package for Meta-Analysis,,2022,,    ,['citation-other']," Meta: General Package for Meta-Analysis. Schwarzer G, Version 5.2-0. The R Project, 2022. Available at cran.r-project.org/package=meta.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Meta:+General+Package+for+Meta-Analysis&author=G+Schwarzer&publication_year=2022&hl=en'],,, Meta 2022 [Computer program] ,additional,CD015395-bbs2-0059,,41674774,,,,,,41674774
CD015395-bib-0068,"Metzendorf MI, Weibel S, Reis S, McDonald S. ",A pragmatic and open science-based solution to a current problem in the reporting of Living Systematic Reviews – the Cochrane Review on nirmatrelvir/ritonavir (Paxlovid®),,,,". Manuscript submitted to publication, 2 June 2022.   ",['citation-other']," Metzendorf MI, Weibel S, Reis S, McDonald S. A pragmatic and open science-based solution to a current problem in the reporting of Living Systematic Reviews – the Cochrane Review on nirmatrelvir/ritonavir (Paxlovid®). Manuscript submitted to publication, 2 June 2022.    ",[],,, Metzendorf 2022 ,additional,CD015395-bbs2-0060,,,,,,,,
CD015395-bib-0069,,Medicines Patent Pool,,,,. medicinespatentpool.org/who-we-are/about-us (accessed 1 December 2021).   ,['citation-other'], Medicines Patent Pool (MPP). Medicines Patent Pool. medicinespatentpool.org/who-we-are/about-us (accessed 1 December 2021).    ,[],,, MPP 2021a ,additional,CD015395-bbs2-0061,,41692648,,,,,,41692648
CD015395-bib-0070,Medicines Patent Pool (MPP). ,Nirmatrelvir - License agreement; November 2021,,,,. Available at medicinespatentpool.org/licence-post/pf-07321332.   ,['citation-other'], Medicines Patent Pool (MPP). Nirmatrelvir - License agreement; November 2021. Available at medicinespatentpool.org/licence-post/pf-07321332.    ,[],,, MPP 2021b ,additional,CD015395-bbs2-0062,,,,,,,,
CD015395-bib-0071,NCT04501978. ,ACTIV-3: Therapeutics for Inpatients with COVID-19 (TICO),,,," [A multicenter, adaptive, randomized, blinded controlled trial of the safety and efficacy of investigational therapeutics for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/NCT04501978 (first received 6 August 2020).   ",['citation-other']," NCT04501978. ACTIV-3: Therapeutics for Inpatients with COVID-19 (TICO) [A multicenter, adaptive, randomized, blinded controlled trial of the safety and efficacy of investigational therapeutics for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/NCT04501978 (first received 6 August 2020).    ",[],,, NCT04501978 ,additional,CD015395-bbs2-0063,,39922466,,,,,,39922466
CD015395-bib-0072,NCT04535167. ,"First-in-human study to evaluate safety, tolerability, and pharmacokinetics following single ascending and multiple ascending doses of PF-07304814 in hospitalized participants with COVID-19",,,," [A phase 1B, 2-part, double-blind, placebo-controlled, sponsor-open study, to evaluate the safety, tolerability and pharmacokinetics of single ascending (24-hour, part 1) and multiple ascending (120-hour, part 2) intravenous infusions of PF-07304814 in hospitalized participants with COVID-19]. clinicaltrials.gov/ct2/show/NCT04535167 (first received 1 September 2020).   ",['citation-other']," NCT04535167. First-in-human study to evaluate safety, tolerability, and pharmacokinetics following single ascending and multiple ascending doses of PF-07304814 in hospitalized participants with COVID-19 [A phase 1B, 2-part, double-blind, placebo-controlled, sponsor-open study, to evaluate the safety, tolerability and pharmacokinetics of single ascending (24-hour, part 1) and multiple ascending (120-hour, part 2) intravenous infusions of PF-07304814 in hospitalized participants with COVID-19]. clinicaltrials.gov/ct2/show/NCT04535167 (first received 1 September 2020).    ",[],,, NCT04535167 ,additional,CD015395-bbs2-0064,,37559753,,,,,,37559753
CD015395-bib-0073,NCT04575597. ,Efficacy and safety of molnupiravir (MK-4482) in non-hospitalized adult participants with covid-19 (MK-4482-002),,,," [A phase 2/3, randomized, placebo-controlled, double-blind clinical study to evaluate the efficacy, safety, and pharmacokinetics of MK-4482 in non-hospitalized adults with COVID-19]. clinicaltrials.gov/ct2/show/NCT04575597 (first received 5 October 2020).   ",['citation-other']," NCT04575597. Efficacy and safety of molnupiravir (MK-4482) in non-hospitalized adult participants with covid-19 (MK-4482-002) [A phase 2/3, randomized, placebo-controlled, double-blind clinical study to evaluate the efficacy, safety, and pharmacokinetics of MK-4482 in non-hospitalized adults with COVID-19]. clinicaltrials.gov/ct2/show/NCT04575597 (first received 5 October 2020).    ",[],,, NCT04575597 ,additional,CD015395-bbs2-0065,,,,,,,,
CD015395-bib-0074,National Health Service (NHS) UK. ,Who cannot have vaccines,,,,. nhs.uk/conditions/vaccinations/why-vaccination-is-safe-and-important/ (accessed 14 December 2021).   ,['citation-other'], National Health Service (NHS) UK. Who cannot have vaccines. nhs.uk/conditions/vaccinations/why-vaccination-is-safe-and-important/ (accessed 14 December 2021).    ,[],,, NHS 2021 ,additional,CD015395-bbs2-0066,,38960458,,,,,,38960458
CD015395-bib-0075,National Institute for Health and Care Excellence (NICE). ,NG191: COVID-19 rapid guideline: managing COVID-19,,,,. nice.org.uk/guidance/ng191 (accessed 14 December 2021).   ,['citation-other'], National Institute for Health and Care Excellence (NICE). NG191: COVID-19 rapid guideline: managing COVID-19. nice.org.uk/guidance/ng191 (accessed 14 December 2021).    ,[],,, NICE 2021 ,additional,CD015395-bbs2-0067,,34181371,,,,,,34181371
CD015395-bib-0076,National Institutes of Health (NIH). ,COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) treatment guidelines,,,,. covid19treatmentguidelines.nih.gov/ (accessed 14 December 2021).   ,['citation-other'], National Institutes of Health (NIH). COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. covid19treatmentguidelines.nih.gov/ (accessed 14 December 2021).    ,[],,, NIH 2021 ,additional,CD015395-bbs2-0068,,40541216,,,,,,40541216
CD015395-bib-0077,"Owen DR, Allerton CM, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. ",An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19, Science ,2021,374,    ,['citation-journal']," Owen DR, Allerton CM, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.  Science 2021;374(6575):1586-93. [PMID: 34726479]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1126/science.abl4784', 'https://www.ncbi.nlm.nih.gov/pubmed/34726479', 'https://scholar.google.com/scholar_lookup?title=An+oral+SARS-CoV-2+Mpro+inhibitor+clinical+candidate+for+the+treatment+of+COVID-19+&author=DR+Owen&author=CM+Allerton&author=AS+Anderson&author=L+Aschenbrenner&author=M+Avery&author=S+Berritt&publication_year=2021&hl=en']",34726479,https://doi.org/10.1126/science.abl4784, Owen 2021 ,additional,CD015395-bbs2-0069,,,,,,,,34726479
CD015395-bib-0078,"Parmar MK, Torri V, Stewart L. ",Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Statistics in Medicine ,1998,17,    ,['citation-journal']," Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.  Statistics in Medicine 1998;17(24):2815-34. [DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8', 'https://www.ncbi.nlm.nih.gov/pubmed/9921604', 'https://scholar.google.com/scholar_lookup?title=Extracting+summary+statistics+to+perform+meta-analyses+of+the+published+literature+for+survival+endpoints+&author=MK+Parmar&author=V+Torri&author=L+Stewart&publication_year=1998&hl=en']",9921604,https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8, Parmar 1998 ,additional,CD015395-bbs2-0070,,9921604,,,,,,9921604
CD015395-bib-0079,"Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. ",Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study, BMJ ,2020,369,    ,['citation-journal']," Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study.  BMJ 2020;369:m1966. [PMID: 32444366]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.m1966', 'https://www.ncbi.nlm.nih.gov/pubmed/32444366', ""https://scholar.google.com/scholar_lookup?title=Factors+associated+with+hospital+admission+and+critical+illness+among+5279+people+with+coronavirus+disease+2019+in+New+York+City:+prospective+cohort+study+&author=CM+Petrilli&author=SA+Jones&author=J+Yang&author=H+Rajagopalan&author=L+O'Donnell&author=Y+Chernyak&publication_year=2020&hl=en""]",32444366,https://doi.org/10.1136/bmj.m1966, Petrilli 2020 ,additional,CD015395-bbs2-0071,,,32444366,,,,,32444366
CD015395-bib-0080,Pfizer Inc. ,Pfizer’s novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study,,,,. pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate (accessed 23 November 2021).   ,['citation-other'], Pfizer Inc. Pfizer’s novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study. pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate (accessed 23 November 2021).    ,[],,, Pfizer 2021 ,additional,CD015395-bbs2-0072,,,,,,,,
CD015395-bib-0081,Pfizer. ,"Potentially Significant Drug Interactions, including Contraindicated DrugsPAXLOVIDTM (nirmatrelvir tablets; ritonavir tablets)",,2022,1.1,:1-9.   ,['citation-other']," Pfizer. Potentially Significant Drug Interactions, including Contraindicated DrugsPAXLOVIDTM (nirmatrelvir tablets; ritonavir tablets). https://pfizermedical.pfizerpro.com/api/vc/en/medical/assets/5773bb0d-ab2b-40bb-8988-be557bd70923/Potentially%20Significant%20Drug%20Interactions.pdf (accessed 20 May 2022)2022;1.1:1-9.    ",[],,, Pfizer 2022 ,additional,CD015395-bbs2-0073,,,,,,,,
CD015395-bib-0082,"Popp M, Stegemann M, Metzendorf M-I, Gould S, Kranke P, Meybohm P, et al. ",Ivermectin for preventing and treating COVID-19, Cochrane Database of Systematic Reviews ,2021,,    ,['citation-journal']," Popp M, Stegemann M, Metzendorf M-I, Gould S, Kranke P, Meybohm P, et al. Ivermectin for preventing and treating COVID-19.  Cochrane Database of Systematic Reviews 2021, Issue 7. Art. No: CD015017. [DOI: 10.1002/14651858.CD015017.pub2]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Ivermectin+for+preventing+and+treating+COVID-19&author=M+Popp&author=M+Stegemann&author=S+Gould&author=P+Kranke&author=P+Meybohm&publication_year=2021&hl=en'],,, Popp 2021a ,additional,CD015395-bbs2-0074,,,,,,,,
CD015395-bib-0083,"Popp M, Stegemann M, Riemer M, Metzendorf M-I, Romero CS, Mikollajewska A, et al. ",Antibiotics for the treatment of COVID-19, Cochrane Database of Systematic Reviews ,2021,,    ,['citation-journal']," Popp M, Stegemann M, Riemer M, Metzendorf M-I, Romero CS, Mikollajewska A, et al. Antibiotics for the treatment of COVID-19.  Cochrane Database of Systematic Reviews 2021, Issue 10. Art. No: CD015025. [DOI: 10.1002/14651858.CD015025]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Antibiotics+for+the+treatment+of+COVID-19&author=M+Popp&author=M+Stegemann&author=M+Riemer&author=CS+Romero&author=A+Mikollajewska&publication_year=2021&hl=en'],,, Popp 2021b ,additional,CD015395-bbs2-0075,,,,,,,,
CD015395-bib-0084,"Popp M, Reis S, Schießer S, Hausinger R Ilona, Stegemann M, et al. ",Ivermectin for preventing and treating COVID-19, Cochrane Database of Systematic Reviews ,2022,,    ,['citation-journal']," Popp M, Reis S, Schießer S, Hausinger R Ilona, Stegemann M, et al. Ivermectin for preventing and treating COVID-19.  Cochrane Database of Systematic Reviews 2022, Issue 6. Art. No: CD015017. [DOI: 10.1002/14651858.CD015017.pub3]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Ivermectin+for+preventing+and+treating+COVID-19&author=M+Popp&author=S+Reis&author=S+Schießer&author=M+Stegemann&publication_year=2022&hl=en'],,, Popp 2022 ,additional,CD015395-bbs2-0076,,,,,,,,
CD015395-bib-0085,"Reis S, Metzendorf M, Kuehn R, Popp M, Gagyor I, Kranke P, et al. ","Living evidence base for Cochrane Review ""Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19""",,,,]   ,['citation-other']," Reis S, Metzendorf M, Kuehn R, Popp M, Gagyor I, Kranke P, et al. Living evidence base for Cochrane Review ""Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19"". osf.io/7g49c/ (created 30 May 2022). [DOI: 10.17605/OSF.IO/7G49C]    ",[],,, Reis 2022a ,additional,CD015395-bbs2-0077,,,,,,,,
CD015395-bib-0086,"Ren SY, Wang WB, Gao RD, Zhou AM. ","Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance", World Journal of Clinical Cases ,2022,10,    ,['citation-journal']," Ren SY, Wang WB, Gao RD, Zhou AM. Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance.  World Journal of Clinical Cases 2022;10(1):1-11. [PMID: 35071500]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.12998/wjcc.v10.i1.1', 'https://www.ncbi.nlm.nih.gov/pubmed/35071500', 'https://scholar.google.com/scholar_lookup?title=Omicron+variant+(B.1.1.529)+of+SARS-CoV-2:+mutation,+infectivity,+transmission,+and+vaccine+resistance+&author=SY+Ren&author=WB+Wang&author=RD+Gao&author=AM+Zhou&publication_year=2022&hl=en']",35071500,https://doi.org/10.12998/wjcc.v10.i1.1, Ren 2022 ,additional,CD015395-bbs2-0078,,35071500,,,,,,35071500
CD015395-bib-0087,,Review Manager Web (RevMan Web),,2020,,. Available at revman.cochrane.org.   ,['citation-other']," Review Manager Web (RevMan Web). Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.    ",[],,, RevMan Web 2020 [Computer program] ,additional,CD015395-bbs2-0079,,41695702,,,,,,41695702
CD015395-bib-0088,"Salvatori G, Luberto L, Maffei M, Aurisicchio L, Roscilli G, Palombo F, et al. ",SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines, Journal of Translational Medicine ,2020,18,    ,['citation-journal']," Salvatori G, Luberto L, Maffei M, Aurisicchio L, Roscilli G, Palombo F, et al. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.  Journal of Translational Medicine 2020;18(1):222. [PMID: 32493510]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/s12967-020-02392-y', 'https://www.ncbi.nlm.nih.gov/pubmed/32493510', 'https://scholar.google.com/scholar_lookup?title=SARS-CoV-2+SPIKE+PROTEIN:+an+optimal+immunological+target+for+vaccines&author=G+Salvatori&author=L+Luberto&author=M+Maffei&author=L+Aurisicchio&author=G+Roscilli&author=F+Palombo&publication_year=2020&hl=en']",32493510,https://doi.org/10.1186/s12967-020-02392-y, Salvatori 2020 ,additional,CD015395-bbs2-0080,,,,,,,,32493510
CD015395-bib-0089,"Schünemann HJ, Higgins JPT Vist GE, Glasziou P, Akl EA, Skoetz N, et al. ","Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022",,,,. Available from training.cochrane.org/handbook.   ,['citation-other']," Schünemann HJ, Higgins JPT Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.    ",[],,, Schünemann 2022 ,additional,CD015395-bbs2-0081,,,,,,,,
CD015395-bib-0090,"Shadmi E, Chen Y, Dourado I, Faran-Perach I, Furler J, Hangoma P, et al. ",Health equity and COVID-19: global perspectives, International Journal for Equity in Health ,2020,19,    ,['citation-journal']," Shadmi E, Chen Y, Dourado I, Faran-Perach I, Furler J, Hangoma P, et al. Health equity and COVID-19: global perspectives.  International Journal for Equity in Health 2020;19(1):104. [PMID: 32586388]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/s12939-020-01218-z', 'https://www.ncbi.nlm.nih.gov/pubmed/32586388', 'https://scholar.google.com/scholar_lookup?title=Health+equity+and+COVID-19:+global+perspectives&author=E+Shadmi&author=Y+Chen&author=I+Dourado&author=I+Faran-Perach&author=J+Furler&author=P+Hangoma&publication_year=2020&hl=en']",32586388,https://doi.org/10.1186/s12939-020-01218-z, Shadmi 2020 ,additional,CD015395-bbs2-0082,,,,,,,,32586388
CD015395-bib-0091,"Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. ",RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ ,2019,366,    ,['citation-journal']," Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials.  BMJ 2019;366:l4898. [DOI: 10.1136/bmj.l4898] [PMID: 31462531]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.l4898', 'https://www.ncbi.nlm.nih.gov/pubmed/31462531', 'https://scholar.google.com/scholar_lookup?title=RoB+2:+a+revised+tool+for+assessing+risk+of+bias+in+randomised+trials&author=JA+Sterne&author=J+Savović&author=MJ+Page&author=RG+Elbers&author=NS+Blencowe&author=I+Boutron&publication_year=2019&hl=en']",31462531,https://doi.org/10.1136/bmj.l4898, Sterne 2019 ,additional,CD015395-bbs2-0083,,,,,,,,31462531
CD015395-bib-0092,"Weibel S, Reis S. ",Supplementary File_Nirmatrelvir_Research Integrity Assessment (Version 1),,2022,,    ,['citation-other']," Weibel S, Reis S. Supplementary File_Nirmatrelvir_Research Integrity Assessment (Version 1). Zenodo2022. [DOI: 10.5281/zenodo.7074190]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Supplementary+File_Nirmatrelvir_Research+Integrity+Assessment+(Version+1)&author=S+Weibel&author=S+Reis&publication_year=2022&hl=en'],,, Supplementary File_Nirmatrelvir_Research Integrity ,additional,CD015395-bbs2-0084,,,,,,,,
CD015395-bib-0093,"Weibel S, Reis S. ",Supplementary File_Nirmatrelvir_Risk of Bias Excel Tool (Version 1),,2022,,    ,['citation-other']," Weibel S, Reis S. Supplementary File_Nirmatrelvir_Risk of Bias Excel Tool (Version 1). Zenodo2022. [DOI: 10.5281/zenodo.7074194]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Supplementary+File_Nirmatrelvir_Risk+of+Bias+Excel+Tool+(Version+1)&author=S+Weibel&author=S+Reis&publication_year=2022&hl=en'],,, Supplementary File_Nirmatrelvir_Risk of Bias ,additional,CD015395-bbs2-0085,,,,,,,,
CD015395-bib-0094,"Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, et al. ",Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant, New England Journal of Medicine ,2022,386,    ,['citation-journal']," Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, et al. Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant.  New England Journal of Medicine 2022;386(10):995-8. [DOI: 10.1056/NEJMc2119407]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1056/NEJMc2119407', 'https://www.ncbi.nlm.nih.gov/pubmed/35081300', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+antibodies+and+antiviral+drugs+against+Covid-19+Omicron+variant&author=E+Takashita&author=N+Kinoshita&author=S+Yamayoshi&author=Y+Sakai-Tagawa&author=S+Fujisaki&author=M+Ito&publication_year=2022&hl=en']",35081300,https://doi.org/10.1056/NEJMc2119407, Takashita 2022 ,additional,CD015395-bbs2-0086,,,,,,,,35081300
CD015395-bib-0095,"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. ",Practical methods for incorporating summary time-to-event data into meta-analysis, Trials ,2007,8,    ,['citation-journal']," Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis.  Trials 2007;8:16. [PMID: 17555582]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/1745-6215-8-16', 'https://www.ncbi.nlm.nih.gov/pubmed/17555582', 'https://scholar.google.com/scholar_lookup?title=Practical+methods+for+incorporating+summary+time-to-event+data+into+meta-analysis&author=JF+Tierney&author=LA+Stewart&author=D+Ghersi&author=S+Burdett&author=MR+Sydes&publication_year=2007&hl=en']",17555582,https://doi.org/10.1186/1745-6215-8-16, Tierney 2007 ,additional,CD015395-bbs2-0087,,17555582,,,,,,17555582
CD015395-bib-0096,"Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. ","Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein", Cell ,2020,183,    ,['citation-journal']," Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein.  Cell 2020;183(6):1735. [PMID: 32155444]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.cell.2020.11.032', 'https://www.ncbi.nlm.nih.gov/pubmed/33306958', 'https://scholar.google.com/scholar_lookup?title=Structure,+function,+and+antigenicity+of+the+SARS-CoV-2+spike+glycoprotein&author=AC+Walls&author=YJ+Park&author=MA+Tortorici&author=A+Wall&author=AT+McGuire&author=D+Veesler&publication_year=2020&hl=en']",33306958,https://doi.org/10.1016/j.cell.2020.11.032, Walls 2020 ,additional,CD015395-bbs2-0088,,33306958,,,,,,33306958
CD015395-bib-0097,"Wang C, Han B, Zhao T, Liu H, Liu B, Chen L, et al. ","Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: a national cross-sectional study", Vaccine ,2021,39,    ,['citation-journal']," Wang C, Han B, Zhao T, Liu H, Liu B, Chen L, et al. Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: a national cross-sectional study.  Vaccine 2021;39(21):2833-42. [PMID: 33896661]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2021.04.020', 'https://www.ncbi.nlm.nih.gov/pubmed/33896661', 'https://scholar.google.com/scholar_lookup?title=Vaccination+willingness,+vaccine+hesitancy,+and+estimated+coverage+at+the+first+round+of+COVID-19+vaccination+in+China:+a+national+cross-sectional+study+&author=C+Wang&author=B+Han&author=T+Zhao&author=H+Liu&author=B+Liu&author=L+Chen&publication_year=2021&hl=en']",33896661,https://doi.org/10.1016/j.vaccine.2021.04.020, Wang 2021 ,additional,CD015395-bbs2-0089,,,,,,,,33896661
CD015395-bib-0098,"Watson J, Whiting PF, Brush JE. ",Interpreting a Covid-19 test result, BMJ ,2020,369,    ,['citation-journal']," Watson J, Whiting PF, Brush JE. Interpreting a Covid-19 test result.  BMJ 2020;369:m1808. [DOI: 10.1136/bmj.m1808]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.m1808', 'https://www.ncbi.nlm.nih.gov/pubmed/32398230', 'https://scholar.google.com/scholar_lookup?title=Interpreting+a+Covid-19+test+result&author=J+Watson&author=PF+Whiting&author=JE+Brush&publication_year=2020&hl=en']",32398230,https://doi.org/10.1136/bmj.m1808, Watson 2020 ,additional,CD015395-bbs2-0090,,32398230,,,,,,32398230
CD015395-bib-0099,"Weibel S, Popp M, Reis S, Skoetz N, Garner P, Sydenham E. ",Identifying and managing problematic trials: a Research Integrity Assessment (RIA) tool for randomized controlled trials in evidence synthesis,,,,]   ,['citation-other']," Weibel S, Popp M, Reis S, Skoetz N, Garner P, Sydenham E. Identifying and managing problematic trials: a Research Integrity Assessment (RIA) tool for randomized controlled trials in evidence synthesis. www.medrxiv.org/content/10.1101/2022.05.31.22275756v1 (first received 05 June 2022). [DOI: 10.1101/2022.05.31.22275756]    ",[],,, Weibel 2022 ,additional,CD015395-bbs2-0091,,36054583,,,,,,36054583
CD015395-bib-0100,"Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, et al. ",PRISMA-Equity 2012 Extension: reporting guidelines for systematic reviews with a focus on health equity, PLOS Medicine ,2012,9,    ,['citation-journal']," Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, et al. PRISMA-Equity 2012 Extension: reporting guidelines for systematic reviews with a focus on health equity.  PLOS Medicine 2012;9(10):e1001333. [DOI: 10.1371/journal.pmed.1001333]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1371/journal.pmed.1001333', 'https://www.ncbi.nlm.nih.gov/pubmed/23222917', ""https://scholar.google.com/scholar_lookup?title=PRISMA-Equity+2012+Extension:+reporting+guidelines+for+systematic+reviews+with+a+focus+on+health+equity+&author=V+Welch&author=M+Petticrew&author=P+Tugwell&author=D+Moher&author=J+O'Neill&author=E+Waters&publication_year=2012&hl=en""]",23222917,https://doi.org/10.1371/journal.pmed.1001333, Welch 2012 ,additional,CD015395-bbs2-0092,,,,,,,,23222917
CD015395-bib-0101,"Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. ","Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis", Annals of Medicine ,2022,54(1),    ,['citation-journal']," Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis.  Annals of Medicine 2022;54(1):516-23. [DOI: 10.1080/07853890.2022.2034936]    Link to article     Google Scholar     ","['https://doi.org/10.1080/07853890.2022.2034936', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+three+new+oral+antiviral+treatment+(molnupiravir,+fluvoxamine+and+Paxlovid)+for+COVID-19:+a+meta-analysis+&author=W+Wen&author=C+Chen&author=J+Tang&author=C+Wang&author=M+Zhou&author=Y+Cheng&publication_year=2022&hl=en']",,https://doi.org/10.1080/07853890.2022.2034936, Wen 2022 ,additional,CD015395-bbs2-0093,,,35118917,,,,,35118917
CD015395-bib-0102,World Health Organization (WHO). ,International standards for clinical trial registries – 2nd edition. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO,,,,. Available at who.int/ictrp/International_Standards_for_Clinical_Trial_Registration_2018.pdf.   ,['citation-other'], World Health Organization (WHO). International standards for clinical trial registries – 2nd edition. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Available at who.int/ictrp/International_Standards_for_Clinical_Trial_Registration_2018.pdf.    ,[],,, WHO 2018 ,additional,CD015395-bbs2-0094,,,,,,,,
CD015395-bib-0103,World Health Organization (WHO). ,Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19),,,,. who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 24 November 2021).   ,['citation-other'], World Health Organization (WHO). Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 24 November 2021).    ,[],,, WHO 2020 ,additional,CD015395-bbs2-0095,,33843161,,,,,,33843161
CD015395-bib-0104,World Health Organization (WHO). ,Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief,,,,. apps.who.int/iris/handle/10665/331713 (accessed 8 April 2020).   ,['citation-other'], World Health Organization (WHO). Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief. apps.who.int/iris/handle/10665/331713 (accessed 8 April 2020).    ,[],,, WHO 2020a ,additional,CD015395-bbs2-0096,,,,,,,,
CD015395-bib-0105,World Health Organization (WHO). ,Vaccine equity,,,,. who.int/campaigns/vaccine-equity (accessed 14 December 2021).   ,['citation-other'], World Health Organization (WHO). Vaccine equity. who.int/campaigns/vaccine-equity (accessed 14 December 2021).    ,[],,, WHO 2021 ,additional,CD015395-bbs2-0097,,41692648,,,,,,41692648
CD015395-bib-0106,World Health Organization (WHO). ,WHO coronavirus disease (COVID-19) dashboard,,,,. covid19.who.int/table (accessed 23 May 2022).   ,['citation-other'], World Health Organization (WHO). WHO coronavirus disease (COVID-19) dashboard. covid19.who.int/table (accessed 23 May 2022).    ,[],,, WHO 2021a ,additional,CD015395-bbs2-0098,,39521455,,,,,,39521455
CD015395-bib-0107,World Health Organization (WHO). ,Therapeutics and COVID-19: living guideline ,,,version 6,:15-23.   ,['citation-other'], World Health Organization (WHO). Therapeutics and COVID-19: living guideline . app.magicapp.org/#/guideline/nBkO1E/rec/E850m0 24 September 2021 (accessed 23 May 2022);version 6:15-23.    ,[],,, WHO 2021b ,additional,CD015395-bbs2-0099,,41634037,,,,,,41634037
CD015395-bib-0108,"Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. ",Factors associated with COVID-19-related death using OpenSAFELY, Nature ,2020,584,    ,['citation-journal']," Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY.  Nature 2020;584(7821):430-6. [PMID: 32640463]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1038/s41586-020-2521-4', 'https://www.ncbi.nlm.nih.gov/pubmed/32640463', 'https://scholar.google.com/scholar_lookup?title=Factors+associated+with+COVID-19-related+death+using+OpenSAFELY&author=EJ+Williamson&author=AJ+Walker&author=K+Bhaskaran&author=S+Bacon&author=C+Bates&author=CE+Morton&publication_year=2020&hl=en']",32640463,https://doi.org/10.1038/s41586-020-2521-4, Williamson 2020 ,additional,CD015395-bbs2-0100,,,,,,,,32640463
CD015395-bib-0109,World Bank. ,The world by income and region,,,,. datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html (accessed 15 February 2022).   ,['citation-other'], World Bank. The world by income and region. datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html (accessed 15 February 2022).    ,[],,, World Bank 2022 ,additional,CD015395-bbs2-0101,,41692482,,,,,,41692482
CD015395-bib-0110,"Wu Z, McGoogan JM. ",Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention, JAMA ,2020,323,    ,['citation-journal']," Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention.  JAMA 2020;323(13):1239-42. [PMID: 32091533]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jama.2020.2648', 'https://www.ncbi.nlm.nih.gov/pubmed/32091533', 'https://scholar.google.com/scholar_lookup?title=Characteristics+of+and+important+lessons+from+the+coronavirus+disease+2019+(COVID-19)+outbreak+in+China:+summary+of+a+report+of+72314+cases+from+the+Chinese+Center+for+Disease+Control+and+Prevention+&author=Z+Wu&author=JM+McGoogan&publication_year=2020&hl=en']",32091533,https://doi.org/10.1001/jama.2020.2648, Wu 2020 ,additional,CD015395-bbs2-0102,,,,,,,,32091533
CD015395-bib-0111,"Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. ",Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors, Science ,2020,368,    ,['citation-journal']," Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.  Science 2020;368(6489):409-12. [PMID: 32198291]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1126/science.abb3405', 'https://www.ncbi.nlm.nih.gov/pubmed/32198291', 'https://scholar.google.com/scholar_lookup?title=Crystal+structure+of+SARS-CoV-2+main+protease+provides+a+basis+for+design+of+improved+α-ketoamide+inhibitors+&author=L+Zhang&author=D+Lin&author=X+Sun&author=U+Curth&author=C+Drosten&author=L+Sauerhering&publication_year=2020&hl=en']",32198291,https://doi.org/10.1126/science.abb3405, Zhang 2020 ,additional,CD015395-bbs2-0103,,,,,,,,32198291
CD015395-bib-0112,"Zhang Y, Tang LV. ",Overview of targets and potential drugs of SARS-CoV-2 according to the viral replication, Journal of Proteome Research ,2021,20,    ,['citation-journal']," Zhang Y, Tang LV. Overview of targets and potential drugs of SARS-CoV-2 according to the viral replication.  Journal of Proteome Research 2021;20(1):49-59. [PMID: 33347311]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1021/acs.jproteome.0c00526', 'https://www.ncbi.nlm.nih.gov/pubmed/33347311', 'https://scholar.google.com/scholar_lookup?title=Overview+of+targets+and+potential+drugs+of+SARS-CoV-2+according+to+the+viral+replication&author=Y+Zhang&author=LV+Tang&publication_year=2021&hl=en']",33347311,https://doi.org/10.1021/acs.jproteome.0c00526, Zhang 2021 ,additional,CD015395-bbs2-0104,,,,,,,,33347311
CD015395-bib-0113,"Reis S, Popp M, Kuehn R, Metzendorf M-I, Gagyor I, Kranke P, et al. ",Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19, Cochrane Database of Systematic Reviews ,2022,,    ,['citation-journal']," Reis S, Popp M, Kuehn R, Metzendorf M-I, Gagyor I, Kranke P, et al. Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19.  Cochrane Database of Systematic Reviews 2022, Issue 4. Art. No: CD015395. [DOI: 10.1002/14651858.CD015395]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Nirmatrelvir+combined+with+ritonavir+for+preventing+and+treating+COVID‐19&author=S+Reis&author=M+Popp&author=R+Kuehn&author=I+Gagyor&author=P+Kranke&publication_year=2022&hl=en'],,, Reis 2022 ,other_versions,CD015395-bbs2-0105,,,,,,,,
